BTIG Maintains Buy on GeneDx Holdings, Lowers Price Target to $90

Benzinga Newsdesk www.benzinga.com Neutral 53.5%

Neg 0% Neu 53.5% Pos 0%

BTIG analyst Mark Massaro maintains GeneDx Holdings (NASDAQ:WGS) with a Buy and lowers the price target from $170 to $90.